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1. INTRODUCTION {#cam42326-sec-0005}
===============

Pancreatic cancer is an aggressive neoplasm with a median survival of approximately 1 year.[1](#cam42326-bib-0001){ref-type="ref"} For early stage pancreatic cancer, definitive management is attained through surgical resection followed by adjuvant chemotherapy (C) with or without chemoradiation (CRT). Several key studies have drawn conflicting conclusions regarding the use of CRT in this population.[2](#cam42326-bib-0002){ref-type="ref"}, [3](#cam42326-bib-0003){ref-type="ref"}, [4](#cam42326-bib-0004){ref-type="ref"} RTOG 9704 evaluated the outcome in resected pancreatic cancer of 3 weeks of postoperative C followed by CRT and further C. This trial demonstrated a potential survival advantage of patients receiving adjuvant C and CRT, but was limited in study design by patients receiving a short duration of C prior to CRT and by prolonged interruptions to C during treatment.[3](#cam42326-bib-0003){ref-type="ref"}

Optimal management for unresectable locally advanced pancreatic cancer (LAPC) using C and CRT is also under investigation. Several studies have shown promising efficacy in LAPC treatment utilizing regimens involving induction C followed by CRT.[5](#cam42326-bib-0005){ref-type="ref"}, [6](#cam42326-bib-0006){ref-type="ref"}, [7](#cam42326-bib-0007){ref-type="ref"} A recent literature review of LAPC prospective studies showed a survival benefit of induction C and CRT together over C alone when the induction C lasted at least 3 months.[8](#cam42326-bib-0008){ref-type="ref"} Similarly, another study by Faisal et al found a trend toward improved survival in patients with LAPC who received more than two cycles of C prior to CRT.[9](#cam42326-bib-0009){ref-type="ref"}

For both resected early stage pancreatic cancer and unresectable LAPC, the ideal duration of chemotherapy prior to CRT remains unclear. This National Cancer Database (NCDB) study was performed using aggregated hospital registry data to compare outcomes between shorter and longer durations of chemotherapy prior to CRT for pancreatic cancer.

2. METHODS {#cam42326-sec-0006}
==========

2.1. Patient population {#cam42326-sec-0007}
-----------------------

The NCDB registry was queried for patients with pancreatic adenocarcinoma diagnosed between 2004 and 2015 (the most recent dataset available at the time of this study). The NCDB is a national cancer database capturing approximately 70% of the cancer incidence cases in the United States. It also includes over 30 million historical records.[10](#cam42326-bib-0010){ref-type="ref"} This dataset is de‐identified and was exempt from institutional review board\'s review.

Detailed criteria for patient selection are shown in Figure [1](#cam42326-fig-0001){ref-type="fig"}. From our initial query, we selected two patient cohorts: cohorts I‐II for resected stage I‐II, clinical T1‐3N0‐1M0 and cohort III for unresected stage III, clinical T4N0‐1M0 pancreatic adenocarcinoma. Cohort I‐II included patients who had been treated with curative‐intent resection and adjuvant C followed by adjuvant CRT. Cohort III included those who had been treated with curative‐intent induction C followed by CRT. Stage I‐III diseases in 2004‐2015 were based on American Joint Committee on Cancer 6th and 7th editions definitions.

![Flow diagram for patient selection. C: chemotherapy; CRT: chemoradiation](CAM4-8-4110-g001){#cam42326-fig-0001}

All patients received conventionally fractionated radiation therapy (CFRT). To address variability in dose fractionation among hospitals for resected stage I‐II and unresected stage III pancreatic cancer, CFRT was defined as 45‐60 Gy using 1.8‐2.0 Gy/fraction for cohort I‐II and 45‐70 Gy using 1.8‐2.5 Gy/fraction for cohort III.[11](#cam42326-bib-0011){ref-type="ref"}, [12](#cam42326-bib-0012){ref-type="ref"} For cohort I‐II, Whipple surgery was defined as local or partial pancreatectomy and duodenectomy with partial gastrectomy. Whipple‐variant surgery was characterized as partial pancreatectomy with duodenectomy, total pancreatectomy alone, or total pancreatectomy with subtotal gastrectomy or duodenectomy.[13](#cam42326-bib-0013){ref-type="ref"} For both cohorts, those treated with C or radiation therapy within 30 days of each other were considered to have received concurrent CRT alone and were excluded from our analysis. Patients treated with C within 31‐180 days prior to the radiation therapy were considered to have received postoperative C followed by CRT for cohort I‐II and induction C followed by CRT for cohort III.[14](#cam42326-bib-0014){ref-type="ref"} Patients treated with C more than 180 days prior to radiation therapy were excluded.

Exclusion criteria were incomplete follow‐up or vital status data, metastatic pancreatic cancer, palliative‐intent treatments, neoadjuvant C or radiation, missing radiation dose or fractionation information, having no C or radiation therapy, having surgery for cohort III, incomplete data on the number of days between diagnosis and treatments, and patients with post‐diagnosis survival duration of less than 3 months.

For cohort I‐II, baseline characteristics for analysis were treatment facility type, age, gender, race, insurance, household income, residential setting, Charlson‐Deyo comorbidity score (CDS), year of diagnosis, primary tumor site within pancreas, tumor grade, tumor size, clinical T and N stages, pathologic T and N stages, surgery type, surgical margin, single‐ vs multi‐agent C, total radiation dose and fractionation, and the number of days between the onset of C and CRT. For cohort III, its baseline characteristics were similar to the aforementioned variables, except for pathologic T and N stages, surgery type, surgical margin, since no surgery was performed in this cohort. For cohort I‐II, surgical margin was categorized as either negative (R0) or positive (R1, R2, positive margin not otherwise specified). Patients were stratified by age ≥65 years or \<65 years for both cohorts, tumor size \<3.0 cm or ≥3.0 cm for cohort I‐II, and tumor size \<3.8 cm or ≥3.8 cm for cohort III based on their median values. For each cohort, short (short C) and long (long C) duration of chemotherapy prior to CRT were determined based on the median values of the number of days between the start of C and radiation therapy. The household income level of each patient\'s residential area was according to the 2012 American Community Survey data adjusted for inflation (the most recent data at the time of this study), and it was categorized by above or below the median value of \$48 000.

Pertinent prognostic factors, such as type and duration of chemotherapy, and patient performance status are unavailable in the NCDB. Other outcomes, such as local and distant failure and toxicity data are also unavailable in the dataset. For cohort I‐II, CA 19‐9 factor was excluded for analysis, since 439 patients (52.3%) had missing values and 176 patients (21.0%) had unknown values above 98 U/mL. For cohort III, tumor grade was excluded for analysis, since 583 patients (79.0%) had missing values. For this cohort, 288 patients (39.0%) had missing values for CA 19‐9 factor and another 264 patients (35.8%) had unknown values above 98 U/mL. CA 19‐9 level was also excluded for analysis in cohort III. The primary endpoint was overall survival (OS), defined as time between the diagnosis and the last follow‐up or death.

2.2. Statistical analysis {#cam42326-sec-0008}
-------------------------

Overall survival was examined using Kaplan‐Meier and log‐rank tests. Categorical and continuous variables between the short and long C groups were compared using Fisher\'s exact and Mann‐Whitney U tests, respectively. Logistic regression univariate (UVA) and multivariate analyses (MVA) were used to determine predictors for the receipt of long C and were indicated as odds ratio (OR). Cox proportional hazard UVA and MVA were used to determine predictors for the OS and were indicated as hazards ratio (HR). MVA models were constructed using all statistically significant factors from UVA and were finalized based on a backward stepwise elimination. Treatment interactions with other variables were examined using Cox MVA by adding interaction terms.[15](#cam42326-bib-0015){ref-type="ref"}

In order to reduce selection bias, propensity score matching was performed based on baseline characteristics. For cohort I‐II, these characteristics include facility type, age, CDS, tumor grade, tumor size, year of diagnosis, pathologic T and N stages, surgery type, surgical margin, single‐ vs multi‐agent chemotherapy use, and total radiation dose. For cohort III, baseline characteristics for matching included aforementioned variables from cohort I‐II in addition to clinical N stage, except for tumor grade, pathologic T and N stages, surgery type, and surgical margin. Additional variables were considered for matching if they were statistically significant in Cox MVA for OS. All matching was performed in a 1:1 ratio without replacements based on the nearest neighbor method with a caliper distance of 0.2 of the standard deviation of the logit of the propensity score.[16](#cam42326-bib-0016){ref-type="ref"} MatchIt package (version 3.0.1) was used for matching. After matching, matched‐sample Cox UVA was performed to evaluate the survival benefit of long C. All aforementioned analyses were performed using R software (version 3.4.3, R Foundation for Statistical Computing, Vienna, Austria). All p values were two‐sided and those less than 0.05 were considered statistically significant.

3. RESULTS {#cam42326-sec-0009}
==========

3.1. Cohort I‐II {#cam42326-sec-0010}
----------------

A total of 1577 patients with clinical stage I‐III pancreatic adenocarcinoma met the inclusion criteria and were identified. Of those, 839 patients with resected stage I‐II, clinical T1‐3N0‐1M0 pancreatic adenocarcinoma received postoperative C followed by CRT. The median value of the number of days between the onset of C and CRT in this cohort was 70 days. Short C and long C were stratified by \<70 (n = 409) and ≥70 days (n = 430), respectively. Short C had a median of 45 days (interquartile range \[IQR\] 35‐57) and long C had a median of 109 days (IQR 85‐138; *P* \< 0.001) between the start of C and CRT. The majority of patients had stage II pathologic T3N1M0 moderately or poorly differentiated adenocarcinoma of the pancreatic head (Table [1](#cam42326-tbl-0001){ref-type="table"}). The long C group had more patients with negative surgical margins and who were treated with single‐agent chemotherapy. Other variables were well balanced.

###### 

Baseline characteristics for cohort I‐II, before and after matching

                              Before matching   After matching                                                            
  --------------------------- ----------------- ---------------- ------ ----------- ----------- ------ ---- ------ ------ ------
  Facility                                                                          0.94                                  0.87
  Nonacademic                 259               63               272    63                      195    64   198    65      
  Academic                    145               35               154    36                      110    36   107    35      
  NA                          5                 1                4      1                       0      0    0      0       
  Age                                                                               0.19                                  0.57
  \<65                        205               50               236    55                      155    51   163    53      
  ≥65                         204               50               194    45                      150    49   142    47      
  NA                          0                 0                0      0                       0      0    0      0       
  Gender                                                                            0.58                                   
  Female                      197               48               216    50                                                 
  Male                        212               52               214    50                                                 
  NA                          0                 0                0      0                                                  
  Race                                                                              0.06                                   
  White                       362               89               362    84                                                 
  Black                       35                9                41     10                                                 
  Other                       11                3                25     6                                                  
  NA                          1                 0                2      0                                                  
  Insurance                                                                         0.90                                   
  None                        11                3                13     3                                                  
  Nonprivate                  211               52               215    50                                                 
  Private                     184               45               198    46                                                 
  NA                          3                 1                4      1                                                  
  Income                                                                            0.88                                   
  Above median                271               66               290    67                                                 
  Below median                132               32               137    32                                                 
  NA                          6                 1                3      1                                                  
  Residential setting                                                   0.30                                              
  Metro                       326               80               358    83                                                 
  Urban                       62                15               50     12                                                 
  Rural                       7                 2                9      2                                                  
  NA                          14                3                13     3                                                  
  Charlson‐Deyo Score                                            0.88                                       1             
  0‐1                         384               94               405    94                      284    93   285    93      
  ≥2                          25                6                25     6                       21     7    20     7       
  NA                          0                 0                0      0                       0      0    0      0       
  Year of diagnosis                                                     0.67                                       0.84   
  2004‐2007                   21                5                23     5                       14     5    12     4       
  2008‐2011                   216               53               214    50                      152    50   148    49      
  2012‐2015                   172               42               193    45                      139    46   145    48      
  NA                          0                 0                0      0                       0      0    0      0       
  Primary tumor site                                                    0.36                                              
  Head                        331               81               364    85                                                 
  Body                        35                9                30     7                                                  
  Tail                        43                11               36     8                                                  
  NA                          0                 0                0      0                                                  
  Tumor grade                                                                       0.28                                  0.24
  Well diff                   33                8                39     9                       26     9    31     10      
  Mod diff                    207               51               216    50                      174    57   162    53      
  Poor diff                   129               32               139    32                      95     31   108    35      
  Other                       11                3                4      1                       10     3    4      1       
  NA                          29                7                32     7                       0      0    0      0       
  Tumor size                                                                        0.40                                  0.87
  \<3.0                       173               42               168    39                      125    41   122    40      
  ≥3.0                        229               56               251    58                      180    59   183    60      
  NA                          7                 2                11     3                       0      0    0      0       
  Clinical T stage                                                      0.06                                              
  1                           56                14               72     17                                                 
  2                           150               37               179    42                                                 
  3                           203               50               179    42                                                 
  NA                          0                 0                0      0                                                  
  Clinical N stage                                                      0.06                                              
  0                           260               64               301    70                                                 
  1                           149               36               129    30                                                 
  NA                          0                 0                0      0                                                  
  Pathologic T stage                                                    0.36                                       0.06   
  0                           0                 0                1      0                       0      0    1      0       
  1                           18                4                16     4                       15     5    11     4       
  2                           36                9                50     12                      23     8    34     11      
  3                           331               81               344    80                      260    85   258    85      
  4                           9                 2                5      1                       7      2    1      0       
  NA                          15                4                14     3                       0      0    0      0       
  Pathologic N stage                                                    0.45                                       0.43   
  0                           83                20               98     23                      62     20   71     23      
  1                           304               74               314    73                      243    80   234    77      
  NA                          22                5                18     4                       0      0    0      0       
  Surgery                                                                           0.76                                  0.72
  Whipple‐variant             115               28               127    30                      90     30   96     31      
  Whipple                     205               50               218    51                      154    50   155    51      
  Other                       89                22               85     20                      61     20   54     18      
  NA                          0                 0                0      0                       0      0    0      0       
  Surgical margin                                                       0.005                                      0.62   
  Negative                    287               70               335    78                      236    77   242    79      
  Positive                    118               29               87     20                      69     23   63     21      
  NA                          4                 1                8      2                       0      0    0      0       
  Chemotherapy                                                          0.03                                       0.46   
  Single‐agent                218               53               261    61                      166    54   176    58      
  Multi‐agent                 191               47               169    39                      139    46   129    42      
  NA                          0                 0                0      0                       0      0    0      0       
  Total radiation dose (Gy)                                      0.16                                       0.73          
  Median                      50.4                               50.4                           50.4        50.4           
  IQR                         50.4‐50.4         50.4‐50.4               50.4‐50.4   50.4‐50.4                             
  Fraction                                                                          0.17                                   
  Median                      28                                 28                                                        
  IQR                         28‐28             28‐28                                                                     

Abbreviation: IQR, interquartile range.

John Wiley & Sons, Ltd

On logistic regression MVA, patients who were neither Caucasian nor African‐American (OR 2.36, *P* = 0.02), and who had received a total radiation dose \>54 Gy (OR 3.25, *P* = 0.002) were more likely to receive long C. In addition, patients with positive surgical margins (OR 0.57, *P* \< 0.001) were less likely to receive long C. No other variables were statistically significant for the receipt of long C.

On Cox MVA (Table [2](#cam42326-tbl-0002){ref-type="table"}), treatments at academic facilities (HR 0.73, *P* = 0.001) and long C (HR 0.72, *P* \< 0.001) showed improved OS. Having moderately (HR 1.60, *P* = 0.01) or poorly (HR 2.21, *P* \< 0.001) differentiated tumors, larger tumors (HR 1.48, *P* \< 0.001), positive pathologic nodal status (HR 1.37, *P* = 0.009), and positive surgical margins (HR 1.33, *P* = 0.005) were associated with worse mortality. After Cox MVA, there was no treatment interaction with age (*P* = 0.60), CDS (*P* = 0.42), or year of diagnosis (2008‐2011, *P* = 0.46; 2012‐2015, *P* = 0.91).

###### 

Cox UVA and MVA for cohort I‐II

  Variable                    Cox UVA   Cox MVA                                   
  --------------------------- --------- ------------ --------- ------ ----------- ---------
  Facility                                                                        
  Nonacademic                 1         Ref                    1      Ref          
  Academic                    0.74      0.63‐0.88    \<0.001   0.73   0.61‐0.88   0.001
  Age                                                                             
  \<65                        1         Ref                                        
  ≥65                         1.08      0.92‐1.27    0.36                          
  Gender                                                                          
  Female                      1         Ref                                        
  Male                        1.06      0.90‐1.25    0.48                          
  Race                                                                            
  White                       1         Ref                                        
  Black                       0.95      0.71‐1.27    0.73                          
  Other                       0.93      0.61‐1.41    0.73                          
  Insurance                                                                       
  None                        1         Ref                                        
  Nonprivate                  0.85      0.53‐1.34    0.48                          
  Private                     0.71      0.44‐1.13    0.15                          
  Income                                                                          
  Above median                1         Ref                    1      Ref          
  Below median                1.20      1.01‐1.42    0.04      1.16   0.96‐1.41   0.12
  Residential setting                                                             
  Metro                       1         Ref                    1      Ref          
  Urban                       0.93      0.73‐1.18    0.54                          
  Rural                       1.88      1.10‐3.20    0.02      1.42   0.79‐2.56   0.24
  Charlson‐Deyo Score                                                             
  0‐1                         1         Ref                                        
  ≥2                          1.10      0.78‐1.54    0.60                          
  Year of diagnosis                                                               
  2004‐2007                   1         Ref                    1      Ref          
  2008‐2011                   0.77      0.56‐1.06    0.11                          
  2012‐2015                   0.68      0.48‐0.95    0.03      0.93   0.61‐1.43   0.75
  Primary tumor site                                                              
  Head                        1         Ref                                        
  Body                        0.97      0.72‐1.30    0.83                          
  Tail                        1.10      0.84‐1.44    0.50                          
  Tumor grade                                                                     
  Well diff                   1         Ref                    1      Ref          
  Mod diff                    1.50      1.07‐2.10    0.02      1.6    1.11‐2.31   0.01
  Poor diff                   1.92      1.36‐2.71    \<0.001   2.21   1.52‐3.23   \<0.001
  Other                       1.64      0.79‐3.39    0.18                          
  Tumor size                                                                      
  \<3.0                       1         Ref                    1      Ref          
  ≥3.0                        1.65      1.39‐1.96    \<0.001   1.48   1.23‐1.78   \<0.001
  Pathologic T stage                                                              
  0                           1         Ref                                        
  1                           0.25      0.034‐1.88   0.18                          
  2                           0.29      0.040‐2.11   0.22                          
  3                           0.39      0.054‐2.76   0.34                          
  4                           0.39      0.049‐3.13   0.38                          
  Pathologic N stage                                                              
  0                           1         Ref                    1      Ref          
  1                           1.49      1.20‐1.84    \<0.001   1.37   1.08‐1.73   0.009
  Surgery                                                                         
  Whipple‐variant             1         Ref                                        
  Whipple                     0.87      0.72‐1.05    0.14                          
  Other                       0.96      0.77‐1.21    0.74                          
  Surgical margin                                                                 
  Negative                    1         Ref                    1      Ref          
  Positive                    1.37      1.14‐1.65    \<0.001   1.33   1.09‐1.63   0.005
  Chemotherapy                                                                    
  Single‐agent                1         Ref                                        
  Multi‐agent                 1.02      0.86‐1.20    0.86                          
  Total radiation dose (Gy)                                                       
  Per 1 Gy increase           0.9997    0.97‐1.03    0.98                          
  Chemo duration                                                                  
  Short C                     1         Ref                    1      Ref          
  Long C                      0.79      0.67‐0.92    0.004     0.72   0.60‐0.86   \<0.001

Abbreviation: HR, hazards ratio.

John Wiley & Sons, Ltd

The overall median follow‐up in cohort I‐II was 39.5 months (IQR 26.3‐58.2). The short C group had a median follow‐up of 37.8 months (IQR 26.5‐58.7) and the long C group had that of 40.3 months (IQR 26.3‐58.1). The median OS for cohort I‐II was 21.9 months (IQR 15.2‐36.6) for the short C group and 25.9 months (IQR 17.6‐41.9) for the long C group (log‐rank *P* = 0.003). OS at 2 years was 49.4% for the short C group and 59.5% for the long C group.

A total of 610 patients were matched, with 305 patients in each group. All variables were well balanced (Table [1](#cam42326-tbl-0001){ref-type="table"}). The median follow‐up was 36.6 months (IQR 24.8‐52.9) for the short C group and 41.0 months (IQR 27.5‐56.0) for the long C group. The median OS was 21.9 months (IQR 14.5‐36.5) for the short C group and 26.1 months (IQR 17.7‐42.1) for the long C group (log‐rank *P* = 0.003). OS at 2 years was 48.6% for the short C group and 60.0% for the long C group (Figure [2](#cam42326-fig-0002){ref-type="fig"}).

![Overall survival for cohort I‐II, after matching. C: chemotherapy](CAM4-8-4110-g002){#cam42326-fig-0002}

3.2. Cohort III {#cam42326-sec-0011}
---------------

A total of 738 patients had unresected stage III, clinical T4N0‐1M0 pancreatic adenocarcinoma and were included in cohort III. The median number of days between the onset of C and CRT in this cohort was 90 days. Short C and long C were stratified by \<90 (n = 360) and ≥90 days (n = 378), respectively. Short C had a median of 67 days (IQR 50‐77) and long C had a median of 119 days (IQR 103‐140; *P* \< 0.001) between the start of C and CRT. The majority of patients had clinical T4N0 adenocarcinoma of the pancreatic head (Table [3](#cam42326-tbl-0003){ref-type="table"}). The long C group was more likely to include patients treated at academic facilities, diagnosed between 2012 and 2015, and who had received multi‐agent chemotherapy.

###### 

Baseline characteristics for cohort III, before and after matching

                              Before matching   After matching                                                            
  --------------------------- ----------------- ---------------- ------ ----------- ----------- ------ ---- ------ ------ ------
  Facility                                                                          0.003                                 0.67
  Nonacademic                 218               61               188    50                      153    56   147    54      
  Academic                    138               38               186    49                      118    44   124    46      
  NA                          4                 1                4      1                       0      0    0      0       
  Age                                                                               0.71                                  0.61
  \<65                        184               51               188    50                      137    51   130    48      
  ≥65                         176               49               190    50                      134    49   141    52      
  NA                          0                 0                0      0                       0      0    0      0       
  Gender                                                                            0.06                                   
  Female                      171               48               207    55                                                 
  Male                        189               53               171    45                                                 
  NA                          0                 0                0      0                                                  
  Race                                                                              0.42                                   
  White                       291               81               317    84                                                 
  Black                       54                15               44     12                                                 
  Other                       11                3                11     3                                                  
  NA                          4                 1                6      2                                                  
  Insurance                                                                         0.73                                   
  None                        8                 2                6      2                                                  
  Nonprivate                  190               53               193    51                                                 
  Private                     160               44               175    46                                                 
  NA                          2                 1                4      1                                                  
  Income                                                                            0.59                                   
  Above median                230               64               249    66                                                 
  Below median                128               36               126    33                                                 
  NA                          2                 1                3      1                                                  
  Residential setting                                                   0.71                                              
  Metro                       288               80               314    83                                                 
  Urban                       49                14               44     12                                                 
  Rural                       7                 2                8      2                                                  
  NA                          16                4                12     3                                                  
  Charlson‐Deyo Score                                            0.11                                       1             
  0‐1                         349               97               357    94                      263    97   262    97      
  ≥2                          11                3                21     6                       8      3    9      3       
  NA                          0                 0                0      0                       0      0    0      0       
  Year of diagnosis                                                     \<0.001                                    0.92   
  2004‐2007                   38                11               21     6                       15     6    16     6       
  2008‐2011                   182               51               137    36                      130    48   125    46      
  2012‐2015                   140               39               220    58                      126    46   130    48      
  NA                          0                 0                0      0                       0      0    0      0       
  Primary tumor site                                                    0.47                                              
  Head                        251               70               254    67                                                 
  Body                        98                27               116    31                                                 
  Tail                        11                3                8      2                                                  
  NA                          0                 0                0      0                                                  
  Tumor size                                                                        0.32                                  0.44
  \<3.8                       151               42               179    47                      127    47   137    51      
  ≥3.8                        173               48               174    46                      144    53   134    49      
  NA                          36                10               25     7                       0      0    0      0       
  Clinical N stage                                                      0.10                                       0.37   
  0                           211               59               245    65                      171    63   182    67      
  1                           149               41               133    35                      100    37   89     33      
  NA                          0                 0                0      0                       0      0    0      0       
  Chemotherapy                                                          \<0.001                                    0.62   
  Single‐agent                119               33               77     20                      71     26   65     24      
  Multi‐agent                 241               67               301    80                      200    74   206    76      
  NA                          0                 0                0      0                       0      0    0      0       
  Total radiation dose (Gy)                                      0.66                                       0.08          
  Median                      50.4                               50.4                           50.4        50.4           
  IQR                         50.4‐54           50.4‐54                 50.4‐54.0   50.4‐54.3                             
  Fraction                                                                          0.16                                   
  Median                      28                                 28                                                        
  IQR                         27‐30             27‐29                                                                     

Abbreviation: IQR, interquartile range.

John Wiley & Sons, Ltd

On logistic MVA, patients treated at academic facilities (OR 1.48, *P* = 0.01), diagnosed between 2012‐2015 (OR 2.65, *P* \< 0.001), and who were treated with multi‐agent chemotherapy (OR 1.66, *P* = 0.004) were associated with the receipt of long C.

On Cox MVA (Table [4](#cam42326-tbl-0004){ref-type="table"}), treatments at academic facilities (HR 0.81, *P* = 0.009), being diagnosed between 2012 and 2015 (HR 0.73, *P* = 0.04), the use of multi‐agent chemotherapy (HR 0.77, *P* = 0.005), and long C duration (HR 0.83, *P* = 0.03) were associated with improved survival. After Cox MVA, no treatment interaction was observed with age (*P* = 0.39), CDS (0.65), year of diagnosis (2008‐2011, *P* = 0.91; 2012‐2015, *P* = 0.77).

###### 

Cox UVA and MVA for cohort III

  Variable                    Cox UVA   Cox MVA                                  
  --------------------------- --------- ----------- --------- ------ ----------- -------
  Facility                                                                       
  Nonacademic                 1         Ref                   1      Ref          
  Academic                    0.76      0.65‐0.89   \<0.001   0.81   0.69‐0.95   0.009
  Age                                                                            
  \<65                        1         Ref                                       
  ≥65                         1.04      0.89‐1.21   0.64                          
  Gender                                                                         
  Female                      1         Ref                   1      Ref          
  Male                        1.19      1.02‐1.39   0.03      1.10   0.93‐1.30   0.25
  Race                                                                           
  White                       1         Ref                                       
  Black                       0.86      0.68‐1.10   0.23                          
  Other                       0.86      0.54‐1.36   0.52                          
  Insurance                                                                      
  None                        1         Ref                                       
  Nonprivate                  1.07      0.57‐2.02   0.82                          
  Private                     1.07      0.57‐2.01   0.83                          
  Income                                                                         
  Above median                1         Ref                                       
  Below median                1.05      0.90‐1.24   0.52                          
  Residential setting                                                            
  Metro                       1         Ref                                       
  Urban                       0.996     0.79‐1.26   0.98                          
  Rural                       1.35      0.80‐2.25   0.26                          
  Charlson‐Deyo Score                                                            
  0‐1                         1         Ref                                       
  ≥2                          1.08      0.75‐1.57   0.67                          
                                                                                 
  2004‐2007                   1         Ref                   1      Ref          
  2008‐2011                   0.95      0.71‐1.28   0.75                          
  2012‐2015                   0.67      0.50‐0.89   0.007     0.73   0.54‐0.98   0.04
  Primary tumor site                                                             
  Head                        1         Ref                                       
  Body                        0.87      0.73‐1.04   0.12                          
  Tail                        1.25      0.78‐2.01   0.35                          
  Tumor size (cm)                                                                
  \<3.8                       1         Ref                   1      Ref          
  ≥3.8                        1.20      1.02‐1.41   0.03      1.17   0.99‐1.38   0.06
  Clinical N stage                                                               
  0                           1         Ref                                       
  1                           1.15      0.98‐1.34   0.09                          
  Chemotherapy                                                                   
  Single‐agent                1         Ref                   1      Ref          
  Multi‐agent                 0.69      0.58‐0.82   \<0.001   0.77   0.65‐0.92   0.005
  Total radiation dose (Gy)                                                      
  Per 1 Gy increase           0.99      0.97‐1.00   0.12                          
  Chemo duration                                                                 
  Short C                     1         Ref                   1      Ref          
  Long C                      0.75      0.64‐0.88   \<0.001   0.83   0.71‐0.98   0.03

Abbreviation: HR, hazards ratio.

John Wiley & Sons, Ltd

The overall median follow‐up was 24.3 months (IQR 16.2‐38.0) for cohort III. The median follow‐up was 23.8 months (IQR 12.9‐33.0) for the short C group and 24.6 months (IQR 17.7‐40.4) for the long C group. The median OS was 14.0 months (IQR 9.5‐22.0) for the short C group and 17.4 months (13.0‐24.3) for the long C group (log‐rank *P* \< 0.001). OS at 2 years was 23.6% for the short C group and 30.2% for the long C group.

A total of 542 patients were matched, with 271 patients in each group. All variables were well balanced (Table [3](#cam42326-tbl-0003){ref-type="table"}). The median follow‐up was 23.5 months (IQR 11.3‐32.3) for the short C group and 22.5 months (IQR 13.9‐42.7) for the long C group. The median OS was 14.2 months (IQR 9.2‐21.7) for the short C group and 16.7 months (IQR 13.0‐23.3) for the long C group (log‐rank *P* = 0.02). OS at 2 years was 22.8% for the short C group and 26.3% for the long C group (Figure [3](#cam42326-fig-0003){ref-type="fig"}).

![Overall survival for cohort III, after matching**.** C: chemotherapy](CAM4-8-4110-g003){#cam42326-fig-0003}

4. DISCUSSION {#cam42326-sec-0012}
=============

To the best of our knowledge, this study is the first to show that longer duration of chemotherapy prior to CRT improves survival outcomes for stage I‐II and stage III pancreatic cancer using aggregated hospital registry data. We found that longer duration of chemotherapy showed improved OS in the multivariable analysis in both cohort I‐II (HR 0.72, *P* \< 0.001) and cohort III (HR 0.83, *P* = 0.03). After 1:1 propensity score matching, long C remained statistically significant for improved OS compared with short C in both cohort I‐II (median OS 26.1 vs 21.9 months; 2‐year OS 60.0% vs 48.6%; *P* = 0.003) and cohort III (median OS 16.7 vs 14.2 months; 2‐year OS 26.3% vs 22.8%; *P* = 0.02).

Reasons for survival benefit in longer duration of C are not clear. It could be the case that patients who are able to receive longer courses of C are better able to tolerate the associated toxicities. As performance status is unable to be assessed in the NCDB, it is likely that patients receiving long C had more robust performance compared to those unable to tolerate long C. Alternatively, those who received a shorter duration of chemotherapy could have experienced more treatment‐related adverse events. However, since they all received radiation therapy, such adverse events may have been reversible prior to the initiation of radiation. A longer course of chemotherapy may have treated micrometastasis more effectively prior to the local treatment using radiation which is supported by our finding that two‐thirds of stage I‐II patients with cN0 disease were upstaged to pN1. It is also possible that those with shorter chemotherapy duration have less responsive tumor biology. Among patients with stage I‐II pancreatic cancer, scans for restaging are not routinely performed post‐chemotherapy and pre‐CRT to determine the duration of chemotherapy. The duration of chemotherapy was likely determined prior to its initiation. Among patients with stage III pancreatic cancer, scans for restaging post‐chemotherapy and pre‐CRT are sometimes performed, but likely not as routinely as post‐CRT. However, such data are not captured in the NCDB.

In RTOG 9704, patients with stage I‐II pancreatic cancer were treated with 3 weeks of C, followed by a 1‐2 week treatment break, before starting CRT.[3](#cam42326-bib-0003){ref-type="ref"} Similarly in the EORTC‐FFCD‐GERCOR trial, patients received two cycles (for a total of 8 weeks) of C prior to CRT.[2](#cam42326-bib-0002){ref-type="ref"} Neither of these trials demonstrated a survival benefit in favor of their experimental arm. Our study demonstrated that patients with resected, stage I‐II pancreatic cancer who received more than 70 days of C prior to CRT had better survival, suggesting patients included in RTOG 9704 and the EORTC‐FFCD‐GERCOR trials may have not received a long enough course of C before initiating CRT to demonstrate improved survival.

It has been previously demonstrated that FOLFIRINOX is superior to gemcitabine for metastatic disease and was recently shown to significantly increase survival in the adjuvant setting.[17](#cam42326-bib-0017){ref-type="ref"}, [18](#cam42326-bib-0018){ref-type="ref"} Despite this, in the adjuvant setting, the FOLFIRINOX group had fewer patients receive all planned cycles of chemotherapy and a greater number of patients experience a delay and even a chemotherapy dose modification. Therefore, it is possible that our findings result from improved survival from the more active, but increasingly toxic FOLFIRINOX regimen. It is important to note that after matching, both groups had equal proportion of patients receiving multi‐agent chemotherapy. Our findings are further supported by MVA showing improved survival with multi‐agent chemotherapy and treatment occurring after publication of Conroy et al in 2011.

Improved OS with longer duration of C was found in unresected LAPC as well. This is consistent with a single‐institution retrospective report and a large meta‐analysis examining outcomes of induction C followed by CRT.[8](#cam42326-bib-0008){ref-type="ref"}, [9](#cam42326-bib-0009){ref-type="ref"} In the Johns Hopkins experience, treating patients with at least three cycles of C prior to CRT trended toward better OS.[9](#cam42326-bib-0009){ref-type="ref"} Similarly, the meta‐analysis noted a significant OS benefit when induction C lasted at least 3 months, which is the same threshold for improved survival found in our study.[8](#cam42326-bib-0008){ref-type="ref"}

Due to the nature of a national registry‐based study, these results are limited by incomplete patient information and errors in documentation. One area particularly relevant to our report is the lack of toxicity outcomes in the NCDB. It is possible we found worse survival associated with shorter C because some patients experienced toxicities that required early discontinuation of C prior to CRT. However, without toxicity information this is difficult to assess. Further, the NCDB does not contain data on response to treatment, therefore it is unknown if patients with a poor response to chemotherapy also required early discontinuation of C prior to CRT. Despite the propensity score matching, we agree with multilevel selection bias as inherent limitations of NCDB and unavailable variables, such as performance status, types, and number of completed cycles of chemotherapy. Importantly, patient populations in rural, smaller hospitals are less likely captured by NCDB, and NCDB reports may not be representative of their clinical outcomes. In spite of these drawbacks, the NCDB contains the majority of cancer patients treated in the United States and provides a large cohort not otherwise accessible through single‐institution experiences. Ongoing clinical trials looking at various C and CRT combinations for treating pancreatic cancer, such as RTOG 0848, should provide greater insight into the optimal management for this challenging population.

We believe this is the first study using the NCDB to evaluate the ideal duration of chemotherapy prior to CRT for stage I‐II and stage III pancreatic cancer. Our study using propensity score‐matched analysis showed a significant survival benefit for patients who received a longer duration of chemotherapy compared to those undergoing a shorter duration course. This survival benefit was demonstrated in both resected stage I‐II and unresected stage III pancreatic cancer patients. Further prospective studies investigating the optimal length of chemotherapy in the management of pancreatic cancer are warranted.
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